.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EG01_Temsirolimus.Temsirolimus

Information

Temsirolimus is an mTOR inhibitor used primarily in the treatment of advanced renal cell carcinoma. It is also studied for other malignancies. Temsirolimus is approved for clinical use and is administered intravenously.

Pharmacokinetics

Pharmacokinetic parameters are reported in adult patients with advanced cancer following intravenous administration of 25 mg temsirolimus. Parameters are based on population PK modeling.

References

1. Boni, JP, et al., & Burczynski, ME (2005). Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clinical pharmacology and therapeutics 77(1) 76–89. DOI:10.1016/j.clpt.2004.08.025 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15637533

2. Boni, J, et al., & Hug, B (2009). Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus. Cancer chemotherapy and pharmacology 64(2) 263–270. DOI:10.1007/s00280-008-0865-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19015855

3. Barthélémy, P, et al., & Duclos, B (2013). mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice. Critical reviews in oncology/hematology 88(1) 42–56. DOI:10.1016/j.critrevonc.2013.02.006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23523056

Revisions

• 06/2025 initial generated model